Authors’ reply to Gallagher and Winocour

We thank Gallagher and Winocour for their interest in our work.1 Pioglitazone trials were not designed to assess safety endpoints such as bladder cancer. Consequently, the presence of an imbalance between the randomised groups necessitates further inquiry. While we agree that some early events in the PROactive trial are unlikely to be causally …